Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MilliporeSigma Introduces Parteck M DPI | Contract Pharma

MilliporeSigma Introduces Parteck M DPI

New grade of mannitol designed to improve flow and release characteristics of APIs

MilliporeSigma’s Parteck M DPI for dry powder inhalation (DPI) is a new grade of mannitol designed to improve flow and release characteristics of active pharmaceutical ingredients (APIs) in drugs delivered via dry, inhaled powders. Also, Parteck M DPI in dry powder inhalation formulations has the potential to improve compliance among patients who are lactose intolerant. According to the company, Parteck M DPI offers several advantages when compared with lactose, the only alternative carrier with associated pharmacopeia for dry powder inhalation.
           


 
Mannitol is chemically inert, has low moisture content and is a non-reducing sugar, making it suitable for formulation as it will not react with the API. Unlike lactose, which is derived from animal sources, Parteck M DPI is synthetic and manufactured with plant-based raw materials. 
           
Dry powder inhalation is an important pathway for drug delivery, and overcomes the challenges presented by aerosol formulations and nebulizers. Parteck M DPI helps to further improves dry powder formulations by addressing the shortcomings of lactose when used as a carrier.
           
Parteck M DPI will be incorporated into MilliporeSigma’s Emprove program, which provides online access to regulatory and technical information about the excipient and more than 400 other chemicals as well as filters and single-use components to help facilitate risk assessment and qualification processes.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters